Latest News On FDA

Latest KFF Health News Stories

FDA Overlooked Red Flags In Drugmaker’s Testing of New Depression Medicine

KFF Health News Original

In March, a chemical cousin of the anesthetic and club drug ketamine was approved for the treatment of patients with intractable depression. But critics say studies presented to the FDA provided at best modest evidence it worked and did not include information about the safety of the drug, Spravato, for long-term use.

Prestigiosos hospitales se lanzan al negocio de terapias con células madre no aprobadas

KFF Health News Original

Los tratamientos típicos consisten en inyectar las articulaciones de los pacientes con sus propias células grasas o de médula ósea, o con extractos de plaquetas. No está comprobado científicamente que funcionen.

Podcast: KHN’s ‘What The Health?’ Surprise! Fixing Surprise Medical Bills Is Harder Than it Looks

KFF Health News Original

Joanne Kenen of Politico, Anna Edney of Bloomberg News and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss the efforts to curb “surprise” medical bills to patients who inadvertently get out-of-network care; a look at where the 2020 presidential candidates stand on health; and the Trump administration’s efforts to end HIV in the U.S. Also, Rovner interviews Food and Drug Administration Commissioner Scott Gottlieb, who is leaving his job in early April.

Podcast: KHN’s ‘What The Health?’ The Karma Of Cutting Medicare

KFF Health News Original

Stephanie Armour of The Wall Street Journal, Alice Ollstein of Politico and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss the suggested cuts to health programs in President Donald Trump’s budget proposal, the latest on lawsuits challenging work requirements for Medicaid enrollees and the FDA’s crackdown on e-cigarettes. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week.